MSB Trading - 2020, page-20878

THE INCONVENIENT TRUTH

1- we should have the overwhelming efficacy and we didn't. Now we are in the range to be entitl;e even to ask if the efficacy will be achieved in levels that seduce the market

2- we should have a readouts of heart failure and we didn't receive at that stage .That just fuel the unsafety of investment

3- We were expecting some final ok for GCHD and we receive a pathetic announcement fake as price sensitive informaing a panel with ZERO relevance will analyze the product (with no binding conclusions)

4- Vaccines are advanced all around the world and in weekly basis more and more Institutions showing they achieved a high level of anti-bodies with low or not at all secondary effects

5- Several drugs and therapies are achieving good results. REMDESIVIR 62% and Syn 79%. Both with absolutely low prices and ready to go capacity to supply./

What remains ? GVHD be approve and the ARDS as a secondary usage labels that can provide good upside.

But at that stage the share have NO REASON to be at that levels and not surprise if we will retrace to previous levels of 3.20-3.20

CATO (yes not holding, yes always looking for an entry point and YES ,always saying exact what I believe and not promoting others to buy or sell)